Back to Index
Jesse Lee Berry, MD
Assistant Professor of Clinical Ophthalmology
CHL 4650 Sunset Blvd Off Campus Los Angeles
+1 323 442 6578


Dr. Jesse Berry is the Assistant Director of Ocular Oncology at the USC Eye Institute and Children’s Hospital Los Angeles. In addition, Dr. Berry is Associate Residency Program Director for the Los Angeles County + University of Southern California Ophthalmology residency program. She received her undergraduate and medical degree from Harvard University in Massachusetts. Following her ophthalmology residency at the University of Southern California, she was the assistant chief of service at the Los Angeles County Medical Center. She then completed a fellowship in ocular oncology at Children’s Hospital Los Angeles under the mentorship of Drs. Kim and Murphree. Dr. Berry is the founder of WOO, Women in Ocular Oncology. Her research endeavors focus on clinical outcomes of retinoblastoma and choroidal melanoma.


University of Southern California Excellence in Resident Teaching Award

Society of Heed Fellows

Starr Schulman Fellowship

Department of Health Services Innovation Grant

Doheny Eye Institute Medical Knowledge Award

Center for Eye Research and Education McCleary Grant

Harvard Medical International Initiatives in Research Grant

Nevil & Louise Ford Scholarship Fund

David Rockefeller Center of Latin American Studies Grant

Kappa Alpha Theta Foundation Scholarship

Harvard College Scholarship: Elizabeth Cary Agassiz Scholar

Malcolm Kinsberg Scholarship


Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma. Ophthalmology. 2017 Jun 24. View in: PubMed

Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatr Blood Cancer. 2017 Jun 24. View in: PubMed

Acute Lymphoblastic Leukemia Relapse Presenting as Optic Nerve Infiltration. JAMA Ophthalmol. 2017 Jan 12; 135(1):e164656. View in: PubMed

Acute Hemorrhagic Retinopathy following Intravitreal Melphalan Injection for Retinoblastoma: A Report of Two Cases and Technical Modifications to Enhance the Prevention of Retinal Toxicity. Ocul Oncol Pathol. 2017 Jan; 3(1):34-40. View in: PubMed

Detection and Intraretinal Localization of an 'Invisible' Retinoblastoma Using Optical Coherence Tomography. Ocul Oncol Pathol. 2016 Apr; 2(3):148-52. View in: PubMed

Long-Term Outcomes of Group B Eyes in Patients with Retinoblastoma Treated with Short-Course Chemoreduction: Experience from Children's Hospital Los Angeles/University of Southern California. Ocul Oncol Pathol. 2015 Dec; 2(2):105-11. View in: PubMed

Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling. Brachytherapy. 2015 Sep-Oct; 14(5):718-25. View in: PubMed

Low-Dose Chemoreduction for Infants Diagnosed with Retinoblastoma before 6 Months of Age. Ocul Oncol Pathol. 2015 Feb; 1(2):103-10. View in: PubMed

Outcomes of choroidal melanomas treated with eye physics: a 20-year review. JAMA Ophthalmol. 2013 Nov; 131(11):1435-42. View in: PubMed

Unmet need for corrective eyeglasses: results from a Los Angeles County Hospital survey. Int Ophthalmol. 2012 Jun; 32(3):245-50. View in: PubMed

Sonoporation enhances chemotherapeutic efficacy in retinoblastoma cells in vitro. Invest Ophthalmol Vis Sci. 2011 Jun 01; 52(6):3868-73. View in: PubMed

Seasonal 25-hydroxyvitamin D changes in British postmenopausal women at 57 degrees N and 51 degrees N: a longitudinal study. J Steroid Biochem Mol Biol. 2010 Jul; 121(1-2):459-61. View in: PubMed

Tracheal relaxation induced by potassium channel opening drugs: its antagonism by adrenergic neurone blocking agents. Br J Pharmacol. 1992 Aug; 106(4):813-8. View in: PubMed

Biochemical and electrical aspects of the tracheal relaxant action of AH 21-132. Eur J Pharmacol. 1991 Jan 17; 192(3):417-26. View in: PubMed

Powered bySC CTSI